Fat, diabetes, and liver injury in chronic hepatitis C

Current Gastroenterology Reports

Volumn 6, Issue 1, 2004, Pages 22-29

  Ratziu, Vlad ^a   Trabut, Jean Baptiste ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA2A INTERFERON; ANTIVIRUS AGENT; FATTY ACID; GLUCOSE; LOW DENSITY LIPOPROTEIN; PEGINTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VERY LOW DENSITY LIPOPROTEIN;

BODY MASS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY ACID OXIDATION; FATTY LIVER; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEPATITIS C; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPID PEROXIDATION; LIVER INJURY; MOLECULAR MECHANICS; NONHUMAN; OBESITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; COMORBIDITY; COMPARATIVE STUDY; FEMALE; HOSPITALIZATION; INCIDENCE; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; PROGNOSIS; SURVIVAL;

COMORBIDITY; DIABETES MELLITUS; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; OBESITY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 1442307667     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0022-5     Document Type: Review

References (80)

1. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
2. Mehta AH, Brancati FL, Sulkowski MS, et al.: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000, 133:592-599.
3. Mehta SH, Brancati FL, Strathdee SA, et al.: Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-56.
4. Allison ME, Wreghitt T, Palmer CR, Alexander GJ: Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994, 21:1135-1139.
5. Caronia S, Taylor K, Pagliaro L, et al.: Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 30:1059-1063.
6. Fraser GM, Harman I, Meller N, et al.: Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996, 32:526-530.
7. Grimbert S, Valensi P, Levy-Marchal C, et al.: High prevalence of diabetes mellitus in patients with chronic hepatitis C: a case-control study. Gastroenterol Clin Biol 1996, 20:544-548.
8. Knobler H, Schihmanter R, Zifroni A, et al.: Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000, 75:355-359.
9. Konrad T, Zeuzem S, Toffolo G, et al.: Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection. Digestion 2000, 62:52-59.
10. Mason AL, Lau JY, Hoang N, et al.: Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 29:328-333.
11. Ozyilkan E, Arslan M: Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1996, 91:1480-1481.
12. Petit J-M, Bour J-B, Galland-Jos C, et al.: Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001, 35:279-283.
13. Zein NN, Abdulkarim AS, Wiesner RH, et al.: Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000, 32:209-217.
14. Gray H, Wreghitt T, Stratton IM, et al.: High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 1995, 12:244-249.
15. Simo R, Hernandez C, Genesca J, et al.: High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996, 19:998-1000.
16. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, et al.: High prevalence of diabetes mellitus among adult beta-thalassaemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1999, 11:1033-1036.
17. Petrides AS, Vogt C, Schulze-Berge D, et al.: Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994, 19:616-627.
18. Dienes HP, Popper H, Arnold W, Lobeck H: Histologic observations in human hepatitis non-A, non-B. Hepatology 1982, 2:562-571.
19. Scheuer PJ, Ashrafzadeh P, Sherlock S, et al.: The pathology of hepatitis C. Hepatology 1992, 15:567-571.
20. Czaja A, Carpenter H, Santrach P, Moore S: Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998, 29:198-206.
21. Bach N, Thung SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992, 15:572-577.
22. Fiore G, Fera G, Napoli N, et al.: Liver steatosis and chronic hepatitis C: a spurious association? Eur J Gastroenterol Hepatol 1996, 8:125-129.
23. Hwang SJ, Luo JC, Chu CW, et al.: Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001, 16:190-195.
24. Gordon SC, Elloway RS, Long JC, Dmuchowski CF: The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993, 18:1338-1343.
25. Delladetsima JK, Rassidakis G, Tassopoulos NC, et al.: Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol 1996, 24:27-32.
26. Poynard T, Ratziu V, McHutchison J, et al.: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
27. Rubbia-Brandt L, Quadri R, Abid K, et al.: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000, 33:106-115.
28. Serfaty L, Andreani T, Giral P, et al.: Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001, 34:428-34.
29. Mihm S, Fayyazi A, Hartmann H, Ramadori G: Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997, 25:735-739.
30. Adinolfi LE, Gambardella M, Andreana A, et al.: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358-1364.
31. Rubbia-Brandt L, Giostra E, Mentha G, et al.: Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001, 35:307.
32. Kumar D, Farrell GC, Fung C, George J: Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002, 36:1266-1272.
33. Westin J, Nordlinder H, Lagging M, et al.: Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002, 37:837-842.
34. Moriya K, Yotsuyanagi H, Shintani Y, et al.: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997, 78:1527-1531.
35. Moriya K, Fujie H, Shintani Y, et al.: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-1067.
36. Perlemuter G, Sabile A, Letteron P, et al.: Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Faseb J 2002, 16:185-194.
37. Lerat H, Honda M, Beard MR, et al.: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122:352-365.
38. Fujie H, Yotsuyanagi H, Moriya K, et al.: Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999, 59:141-145.
39. Barba G, Harper F, Harada T, et al.: Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997, 94:1200-1205.
40. Okuda M, Li K, Beard MR, et al.: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375.
41. Kawamura T, Furusaka A, Koziel MJ, et al.: Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 1997, 25:1014-1021.
42. Pasquinelli C, Shoenberger JM, Chung J, et al.: Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997, 25:719-727.
43. Negro F: Hepatitis C virus and liver steatosis: Is it the virus? Yes it is, but not always. Hepatology 2002, 36:1050-1052.
44. Thomssen R, Bonk S, Propfe C, et al.: Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992, 181:293-300.
45. Sabile A, Perlemuter G, Bono F, et al.: Hepatitis C virus core protein binds to apolipoprotein All and its secretion is modulated by fibrates. Hepatology 1999, 30:1064-1076.
46. Wong VS, Wight DG, Palmer CR, Alexander GJ: Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model. J Clin Pathol 1996, 49:465-469.
47. Ong JP, Younossi ZM, Speer C, et al.: Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001, 21:266-271.
48. Castera L, Hezode C, Roudot-Thoraval F, et al.: Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003, 52:288-292.
49. Ratziu V, Saboury M, Poynard T: Worsening of steatosis and fibrosis progression. Gut 2003, 52:1386-1387.
50. Ratziu V, Munteanu M, Charlotte F, et al., for the LIDO Study Group: Profibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003, 39:1049-1055.
51. Ohata K, Hamasaki K, Toriyama K, et al.: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036-3043.
52. Monto A, Alonzo J, Watson JJ, et al.: Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002, 36:729-736.
53. Ortiz V, Berenguer M, Rayon JM, et al.: Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002, 97:2408-2414.
54. Hourigan LF, MacDonald GE, Purdie D, et al.: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999, 29:1215-1219.
55. McCullough AJ, Falck-Ytter Y: Body composition and hepatic steatosis as precursors for fibrotic liver disease. Hepatology 1999, 29:1328-1330.
56. Clouston AD, Jonsson JR, Purdie DM, et al.: Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001, 34:314-320.
57. Hickman IJ, Clouston AD, Macdonald GA, et al.: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51:89-94.
58. Marfella R, Quagliaro, L, Nappo F, et al.: Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001, 108:635-636.
59. Kashiwagi A, Asahina T, Nishio Y, et al.: Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes 1996, 45:S84-S86.
60. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
61. Igarashi M, Wakasaki H, Takahara N, et al.: Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999, 103:185-195.
62. Guha M, Bai W, Nadler JL, Natarajan R: Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000, 275:17728-17739.
63. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest 1989, 83:1667-1675.
64. Wolff SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991, 10:339-352.
65. Bierhaus A, Chevion S, Chevion M, et al.: Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997, 46:1481-1490.
66. Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM: Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 2001, 34:943-952.
67. Paradis V, Dargere D, Vidaud M, et al.: Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999, 30:968-976.
68. Williams EJ, Gaca MD, Brigstock DR, et al.: Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000, 32:754-761.
69. Letteron P, Fromenty B, Terris B, et al.: Acute and chronic hepatic steatosis lead to in vivo lipid peroxydation in mice. J Hepatol 1996, 24:200-208.
70. Reeves HL, Burt AD, Wood S, Day CP: Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996, 25:677-683.
71. Ikejima K, Honda H, Yoshikawa M, et al.: Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001, 34:288-297.
72. Saxena NK, Ikeda K, Rockey DC, et al.: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002, 35:762-71.
73. Honda H, Ikejima K, Hirose M, et al.: Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002, 36:12-21.
74. Chitturi S, Farrell G, Frost L, et al.: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002, 36:403-409.
75. Kim JK, Kim YJ, Fillmore JJ, et al.: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001, 108:437-46.
76. Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
77. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
78. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
79. Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639-644.
80. McCullough AJ: Obesity and its nurturing effect on hepatitis C. Hepatology 2003, 38:557-559.